Results 231 to 240 of about 1,359,527 (294)

An Anti-VEGF-B Antibody Reduces Abnormal Tumor Vasculature and Enhances the Effects of Chemotherapy. [PDF]

open access: yesCancers (Basel)
Janes PW   +11 more
europepmc   +1 more source

Optimising hypoxia PET imaging and its applications in guiding targeted radiation therapy for non‐small cell lung cancer: a scoping review

open access: yesJournal of Medical Radiation Sciences, Volume 72, Issue 1, Page 106-118, March 2025.
This review article reports that quantification of hypoxic volumes using PET in the pre‐radiation therapy setting is of prognostic value and indicative of treatment response in non‐small cell lung cancer. Abstract Introduction Non‐small cell lung cancer (NSCLC) is the leading cause of cancer‐related death. Definitive treatment includes chemotherapy and
Carol Marks, Michelle Leech
wiley   +1 more source

Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapies. [PDF]

open access: yesSci Transl Med
Lu Z   +31 more
europepmc   +1 more source

Multimodal Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma (PDAC) With Vascular Involvement: What Is the Impact of Radiation on Perioperative Outcomes, Local Control, and Survival?

open access: yesJournal of Surgical Oncology, EarlyView.
ABSTRACT Objectives Neoadjuvant chemoradiation for PDAC with vascular invasion remains understudied. The aim of this study is to compare neoadjuvant chemotherapy with chemoradiation (NAC + CRT) versus neoadjuvant chemotherapy (NAC) for PDAC with vascular involvement.
Dhruv J. Patel   +14 more
wiley   +1 more source

Ultra‐High Frequency Ultrasound Imaging and Quantification of Microvascular Flow in Xenograft Renal Cell Carcinoma in an Avian Chorioallantoic Membrane Model

open access: yesJournal of Ultrasound in Medicine, EarlyView.
Patient‐derived xenograft (PDX) tumor models initiated in avian chorioallantoic membranes (CAM) are under investigation to evaluate the effectiveness of therapeutic options with the objective of personalizing treatments. CAM PDXs paired with ultra‐high frequency ultrasound (UHFUS) imaging could potentially constitute prospective high throughput assays ...
Sara Mar   +5 more
wiley   +1 more source

Ginsenoside Rg1 Ameliorates LPS‐Induced Sepsis‐Associated Lung Injury in Mice via VEGFC/D‐VEGFR3 Signaling‐Mediated Lymphangiogenesis and Lymphatic Remodeling

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Sepsis‐induced acute lung injury (ALI) remains challenging to treat, with conventional anti‐inflammatory therapies offering limited efficacy. The lymphatic system is crucial for removing edema and inflammatory mediators, and its impairment can exacerbate lung injury.
He Wang   +4 more
wiley   +1 more source

Bilateral Ophthalmoplegia After Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma

open access: yesThe Laryngoscope, EarlyView.
The role of immune checkpoint inhibition (ICI) therapy in the treatment of head and neck squamous cell carcinoma (HNSCC) is expanding with increased utilization of neoadjuvant and adjuvant pembrolizumab in the setting of locally advanced disease. This report describes the presentation and management of the first known case of pembrolizumab‐induced ...
Leonard E. Estephan   +3 more
wiley   +1 more source

The Road to a Realistic 3D Model for Estimating R<sub>2</sub> and R<sub>2</sub>* Relaxation Versus Gd-DTPA Concentration in Whole Blood and Brain Tumor Vasculature. [PDF]

open access: yesNMR Biomed
van Dorth D   +11 more
europepmc   +1 more source

Risk of Long‐Term Airway Sequelae and Mortality in Laryngeal Chondrosarcoma

open access: yesThe Laryngoscope, EarlyView.
ABSTRACT Objective In low‐ and intermediate‐grade laryngeal chondrosarcomas, nonradical surgery or even debulking is considered justifiable to preserve laryngeal function. However, tumor‐ and treatment‐related factors affecting the need for reoperation and long‐term risk for tracheostomy remain unclear.
Taru Ilmarinen   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy